Company Overview of OOO "Gepatera"
OOO "Gepatera", a biotechnology company, develops drugs for the prevention and treatment liver disease. It is developing medicine to treat chronic virus Hepatitis B and D. The company was founded in 2011 and is based in the Russian Federation.
Key Executives for OOO "Gepatera"
OOO "Gepatera" does not have any Key Executives recorded.
OOO "Gepatera" Key Developments
Hepatera LLC Announces Positive Interim Results of Phase 2B Clinical Program of Myrcludex B
Nov 28 17
Hepatera LLC and it's development partner MYR GmbH announced positive interim results in MYR 202 clinical trial, a Phase 2b study investigating Myrcudex B in chronic hepatitis delta infection. 120 subjects have been enrolled into this study in 15 centers in Russia and Germany and have completed active treatment phase. After 24 weeks of treatment, Myrcludex demonstrated excellent safety profile with no drug-related SAEs or treatment discontinuations due to the study drug. Patient`s adherence to the treatment was very high. The primary endpoint, HDV RNA decline >2log10 or negativation was met for all doses of Myrcludex B. In the 10mg treatment group, the endpoint was achieved by 76.6% of patients, vs 3.3% in control arm. Median HDV RNA decline was 2.7log10 in 10mg arm, vs. 0.18log10 in control arm. Myrcludex treatment was associated with marked biochemical response in all Myrcludex arms, but not in the control arm. At week 24, 40% of patients in 10mg arm achieved ALT normalization (6.6% in control arm). Median ALT levels in 10mg and control arm were 43 U/L and 76 U/L, respectively. All differences between Myrcludex and control arm were highly statistically significant. Importantly, trends to decrease in liver stiffness and a decrease of intrahepatic HDV RNA levels were observed in Myrcludex arms. The interim results of the trial were presented at the recent American Association for the Study of Liver Diseases Conference by Prof. Heiner Wedemeyer (Hannover Medical School, Germany).
Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Apr 4 17
Hepatera LLC and its development partner MYR GmbH announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection.
Hepatera LLC and MYR GmbH Announce Results of the First-In-Man Phase 1 Study in Healthy Volunteers
Jun 1 16
Hepatera LLC and it's development partner MYR GmbH announced that the results of the first-in-man Phase 1 study in healthy volunteers, and the proof-of-concept Phase 2a study in HBV/HDV co-infected patients were published as two separate back-to-back articles in Journal of Hepatology and are available online.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries